 Creutzfeldt-Jakob disease pituitary growth hormone recipients United magnitude Creutzfeldt-Jakob disease CJD occurrence recipients pituitary-derived human growth hormone HGH epidemiologic follow-up recipients HGH National Hormone Pituitary Program Seven cases CJD population date patients clinical CJD ataxia imbalance altered mentation common initial manifestation sporadic CJD patient preclinical incubation state disease cases HGH recipients therapy cohort average incubation interval midpoint HGH treatment symptoms great majority patients requisite incubation period expression CJD median duration HGH therapy months CJD cases months patients treatment duration pituitary HGH therapy major risk factor CJD